PR98921

GENEVA, Nov. 21, 2022 /PRNewswire=KYODO JBN/ --

RELIEF THERAPEUTICS Holding SA (SIX: RLF) (OTCQB: RLFTF) (RLFTD) ("Relief"), a

Swiss, commercial-stage biopharmaceutical company identifying, developing and

commercializing novel, patent protected products in selected specialty, rare

and ultra-rare disease areas on a global basis, today announced that its wholly

owned subsidiary APR Applied Pharma Research <https://www.apr.ch/> SA ("APR")

has been nominated as a finalist in the 2022 Rare Disease International Film

Festival UnoSguardoRaro.

APR supports and contributes to the first and only European film festival

showcasing films from around the world that address the challenges of life with

a rare disease. APR's short movie, Forward – Live your best life

<https://www.youtube.com/watch?v=1Tio-ltquX8>, was nominated as a finalist

among more than 200 participants by a jury of international experts comprised

of patient associations, health care professionals and film makers. During the

awards ceremony, the jury awarded APR's movie 2 prizes: Special Mention for

Best Campaign and Best Direction.

"With our campaign Live your best life!, we highlight the emotional journey

lived by PKU families, their difficulties in juggling with a strict diet and

protein substitutes, and their eagerness to pursue their full potential in

life," said Paolo Galfetti, Chief Executive Officer of APR, whose real-life

story of becoming a father of a child with PKU inspired the movie. Paolo

Galfetti commented on APR's work for his first child, Riccardo, born with the

condition: "Knowing these products may be helpful for patients and families,

who live with this rare disease, as for health care professionals, is our

biggest reward. I'm proud of working with passionate people and of the results

we achieved together. Being so involved both personally and professionally

makes me even more proud of my son and the determined and energetic young man

he became."

APR's approach was shaped by its ambition of creating a product that can

respond to the needs of PKU patients and resulted in the creation of the PKU

GOLIKE® line, a Food for Special Medical Purposes. APR's experience in

identifying and applying pharmaceutical technologies to improve the efficacy

and tolerability of molecules for common pathologies served as basis for

improving the absorption of amino acid and allowing better metabolic management.

As part of its participation in the festival, APR attended events in Berlin (Il

Kino), Rome (la Casa del Cinema) and Milan (Niguarda hospital). The festival

earned the support of many rare disease associations such as:

- Eurordis <https://www.eurordis.org/> - Rare Disease Europe

- ACHSE Allianz Chronischer Seltener Erkrankungen

<https://www.achse-online.de/de/>

- Uniamo <https://uniamo.org/> - Federazione Italiana Malattie Rare

<https://uniamo.org/>

About PKU GOLIKE®

PKU GOLIKE® is a phenylalanine-free food intended for the dietary management of

phenylketonuria ("PKU"). The product is comprised of a mixture of amino acids

in the form of granules and is available in convenient packets and medical food

bars. Engineered with the Relief's patented Physiomimic™ Technology platform,

PKU GOLIKE® is the first prolonged-release amino acid product, characterized by

a special coating that ensures physiological absorption of the amino acids

mirroring that of natural proteins. In addition, the special coating masks the

unpleasant taste, odor, and aftertaste of the amino acids. PKU GOLIKE® has been

commercially available in the E.U. since 2019 and was launched in the U.S. in

October 2022.

About Relief

Relief is a Swiss, commercial-stage, biopharmaceutical company focused on

identification, development and commercialization of novel, patent protected

products intended for the treatment of rare and ultra-rare diseases including

metabolic disorders, pulmonary diseases, and connective tissue disorders.

Relief's diversified pipeline consists of assets that have the potential to

effectively address significant unmet medical needs, including PKU GOLIKE®,

engineered with the proprietary physiomimic technology, which is the first

prolonged-release amino acid product commercialized for the dietary management

of phenylketonuria ("PKU"). Relief has a collaboration and license agreement

with Acer Therapeutics for the worldwide development and commercialization of

ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of

metabolism, including Urea Cycle Disorders ("UCDs") and Maple Syrup Urine

Disease ("MSUD"). Relief also continues to develop aviptadil for several rare

pulmonary indications. Further, Relief is in clinical development for

APR-TD011, a differentiated acid oxidizing solution of hypochlorous acid

intended for the treatment of epidermolysis bullosa ("EB"), a group of rare,

genetic, life-threatening connective tissue disorders; APR-TD011 has been

granted Orphan Drug Designation by the U.S. Food & Drug Administration. Relief

is commercializing several legacy products via licensing and distribution

partners.

RELIEF THERAPEUTICS Holding SA is listed on the SIX Swiss Exchange under the

symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFTF and RLFTD.

For more information, please visit www.relieftherapeutics.com. Follow Relief on

LinkedIn

<https://www.linkedin.com/company/relief-therapeutics-holding-sa/?viewAsMember=t

rue>.

CONTACT:

RELIEF THERAPEUTICS Holding SA

Jack Weinstein

Chief Financial Officer and Treasurer

contact@relieftherapeutics.com

FOR MEDIA/INVESTOR INQUIRIES:

LifeSci Advisors

Irina Koffler

+1-917-734-7387

ikoffler@lifesciadvisors.com

Disclaimer:

This communication expressly or implicitly contains certain forward-looking

statements concerning RELIEF THERAPEUTICS Holding SA. Such statements involve

certain known and unknown risks, uncertainties and other factors, including

those risks discussed in RELIEF THERAPEUTICS Holding SA's filings with the SIX

and the Securities and Exchange Commission, which could cause the actual

results, financial condition, performance or achievements of RELIEF

THERAPEUTICS Holding SA to be materially different from any future results,

performance or achievements expressed or implied by such forward-looking

statements. RELIEF THERAPEUTICS Holding SA is providing this communication as

of this date and does not undertake to update any forward-looking statements

contained herein as a result of new information, future events or otherwise.

Photo - https://mma.prnewswire.com/media/1952124/Applied_Pharma_Research.jpg

Source:  Applied Pharma Research